OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH)

XLH is characterized by excess FGF23, hypophosphatemia, skeletal deformities, and growth impairment. For the last 40 years, XLH has been treated with multiple daily doses of oral phosphate and active vitamin D (Pi/D). Burosumab, a fully human monoclonal antibody to FGF23, has been approved by the FD...

Descripción completa

Detalles Bibliográficos
Autores principales: Imel, Erik, Whyte, Michael, Munns, Craig, Portale, Anthony, Ward, Leanne, Nilsson, Ola, Simmons, Jill, Padidela, Raja, Namba, Noriyuki, Cheong, Hae Il, Mao, Meng, Chen, Chao-Yin, Skrinar, Alison, San Martin, Javier, Glorieux, Francis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Bone and Mineral Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555067/
http://dx.doi.org/10.1210/js.2019-OR13-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555067/
http://dx.doi.org/10.1210/js.2019-OR13-2

Ejemplares similares